In this update of small molecules in the news for February 2023, we will cover recent: – Molecules in Motion: clinical trial updates and FDA filings – Negative Readouts: halted, discontinued or altered clinical trials – Million-Dollar Molecules: recent M&A’s, IPOs, and other fundraising – Potential Approvals: recent NDA filings and upcoming PDUFA dates – Where…
Search Results
Highlights from Q1 2022 Webinar Part II
Thank you to all of the drug hunters who attended our second drug discovery webinar! You can find the video and slides at the bottom of this page. In part II of this series we covered: Emerging startups, growing drug discovery companies, and IPOs Clinical readouts, positive and negative Big deals and major regulatory actions…
past newsletters
The Drug Hunter e-mail newsletter was launched in Oct. 2020 and has grown to >5,000 subscribers in less than a year. Below are links to examples of our e-mail newsletters that were published in the past. Consider subscribing to get content, free downloadable PDFs, upcoming events, and career highlights directly to your inbox. You can unsubscribe anytime.…
The Molecular Landscape of AI/ML-Assisted Small Molecule Drug Discovery (Part III)
There have been numerous reviews on the impact of AI/ML in drug discovery looking at broad numbers, but with the volume of companies in the space, few have spelled out exactly what these companies are working on to paint a picture of what the landscape of AI/ML in small molecule drug discovery actually looks like…
Drug Discovery Resources
Drug Hunter Resources | Drug Discovery Websites | Drug Discovery Journals | Drug Discovery Books | Drug Discovery Publications Drug Hunter Resources Drug Hunter is a growing, constantly updated repository of comprehensive yet easy-to-read drug discovery resources and references. We’re here so that professionals entering the field won’t need to read dozens of books just…
baxdrostat
What is it? Baxdrostat (RO6836191, CIN-107) is an oral aldosterone synthase (CYP11B2) inhibitor in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism. The molecule is highly selective (>100x) against a cortisol synthesis enzyme, CYP11B1, allowing it to avoid negative effects due to cortisol reduction in the clinic, a longstanding challenge…
